Roche’s satralizumab meets endpoints in inflammatory disorder

2nd December 2019 Uncategorised 0

The drug works by targeting the interleukin-6 receptor, a potential key driver of neuromyelitis optica spectrum disorder.

More: Roche’s satralizumab meets endpoints in inflammatory disorder
Source: News